

1 A one-year hospital-based prospective COVID-19 open-cohort in the Eastern  
2 Mediterranean region: The Khorshid COVID Cohort (KCC) study

3 Ramin Sami <sup>1</sup>, Forogh Soltaninejad <sup>2</sup>, Babak Amra <sup>3</sup>, Zohreh Naderi <sup>4</sup>, Shaghayegh  
4 Haghjooy Javanmard <sup>5</sup>, Bijan Iraj <sup>6</sup>, Somayeh Haji Ahmadi <sup>7</sup>, Azin Shayganfar <sup>8</sup>,  
5 Mehrnegar Dehghan <sup>9</sup>, Nilufar Khademi <sup>10</sup>, Nastaran Sadat Hosseini <sup>11</sup>, Mojgan Mortazavi  
6 <sup>12</sup>, Marjan Mansourian <sup>13,14\*</sup>, Miquel Angel Mañanas <sup>15,16¶</sup>, Hamid Reza Marateb <sup>17,18,19¶</sup>,  
7 Peyman Adibi <sup>20¶</sup>

8 <sup>1</sup>Department of Internal Medicine, School of Medicine, Isfahan University of Medical  
9 Sciences, Isfahan, Iran

10 <sup>2</sup>The Respiratory Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

11 <sup>3</sup>Bamdad Respiratory Research Center, Isfahan University of Medical Sciences, Isfahan,  
12 Iran

13 <sup>4</sup>Department of Pulmonology, University of Medical Science, Isfahan University, Isfahan,  
14 Iran

15 <sup>5</sup>Department of Physiology, School of Medicine, Applied Physiology Research Center,  
16 Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

17 <sup>6</sup>Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical  
18 Sciences, Isfahan, Iran

19 <sup>7</sup>Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran

20 <sup>8</sup>Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran

21 <sup>9</sup>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

22 <sup>10</sup>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

23 <sup>11</sup>School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

24 <sup>12</sup>Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences,  
25 Isfahan, Iran

26 <sup>13</sup> Department of Epidemiology and Biostatistics, School of Health, Isfahan University of  
27 Medical Sciences, Isfahan, Iran

28 <sup>14</sup> Biomedical Engineering Research Centre (CREB), Automatic Control Department  
29 (ESAI), Universitat Politècnica de Catalunya-Barcelona Tech (UPC), Barcelona, Spain

30 <sup>15</sup> Biomedical Engineering Research Centre (CREB), Automatic Control Department  
31 (ESAI), Universitat Politècnica de Catalunya-Barcelona Tech (UPC), Barcelona, Spain

32 <sup>16</sup> Biomedical Research Networking Center in Bioengineering, Biomaterials, and  
33 Nanomedicine (CIBER-BBN), Spain.

34 <sup>17</sup> Biomedical Engineering Department, Engineering Faculty, University of Isfahan,  
35 Isfahan, Iran

36 <sup>18</sup> Biomedical Engineering Research Centre (CREB), Automatic Control Department  
37 (ESAI), Universitat Politècnica de Catalunya-Barcelona Tech (UPC), Barcelona, Spain

38 <sup>19</sup> Machine Learning Department, Isfahan Cardiovascular Research Center (a WHO-  
39 collaborating center), Isfahan University of Medical Sciences, Isfahan, Iran

40 <sup>20</sup> Digestive Diseases Research Center, Isfahan University of Medical Sciences, Isfahan,  
41 Iran

42

43 \* Corresponding author

44 E-mail: [marjan.mansourian@upc.edu](mailto:marjan.mansourian@upc.edu) (MM)

45

46 ¶These authors contributed equally to this work.

## 47 **Abstract**

48 The COVID-19 is rapidly scattering worldwide, and the number of cases in the  
49 Eastern Mediterranean Region is rising. Thus, there is a need for immediate targeted

50 actions. We designed a longitudinal study in a hot outbreak zone to analyze the serial  
51 findings between infected patients for detecting temporal changes from February 2020. In a  
52 hospital-based open-cohort study, patients are followed from admission until one year from  
53 their discharge (the 1st, 4th, 12th weeks, and the first year). The patient recruitment phase  
54 finished at the end of August 2020, and the follow-up continues by the end of August 2021.  
55 The measurements included demographic, socio-economics, symptoms, health service  
56 diagnosis and treatment, contact history, and psychological variables. The signs  
57 improvement, death, length of stay in hospital were considered primary, and impaired  
58 pulmonary function and psychotic disorders were considered main secondary outcomes.  
59 Moreover, clinical symptoms and respiratory functions are being determined in such  
60 follow-ups. Among the first 600 COVID-19 cases, 490 patients with complete information  
61 (39% female; the average age of  $57\pm 15$  years) were analyzed. Seven percent of these  
62 patients died. The three main leading causes of admission were: fever (77%), dry cough  
63 (73%), and fatigue (69%). The most prevalent comorbidities between COVID-19 patients  
64 were hypertension (35%), diabetes (28%), and ischemic heart disease (14%). The  
65 percentage of primary composite endpoints (PCEP), defined as death, the use of mechanical  
66 ventilation, or admission to an intensive care unit was 18%. The Cox proportional-hazards  
67 model for PCEP indicated the following significant risk factors: Oxygen saturation < 80%  
68 (HR= 6.3; [CI 95%: 2.5,15.5]), lymphopenia (HR= 3.5; [CI 95%: 2.2,5.5]), Oxygen  
69 saturation 80%-90% (HR= 2.5; [CI 95%: 1.1,5.8]), and thrombocytopenia (HR= 1.6; [CI  
70 95%: 1.1,2.5]). This long-term prospective Cohort may support healthcare professionals in  
71 the management of resources following this pandemic.

72

## 73 **Introduction**

74

75         The 2019 novel coronavirus disease (COVID-19) epidemic was officially  
76 announced by the World Health Organization (WHO) as an international public health  
77 emergency. Aggressive growth in the number of those affected with COVID-19 makes this  
78 virus such a threat. Patients were assessed for viral pneumonia through the ascertainment  
79 and testing of bronchoalveolar lavage fluid utilizing whole-genome sequencing, cell  
80 cultures, and polymerase chain reaction (PCR). In addition to high mortality rate, the  
81 disease has caused severe psychological problems among patients [1]. The clinical  
82 characteristics of COVID-19 patients were frequently reported [2]. Over 200 countries have  
83 a substantial incidence to date, including countries from the Middle East, North America,  
84 Asia, Australia, and Europe [3]. Currently, when COVID-19 is rapidly scattering  
85 worldwide, and the number of cases in the Middle East is rising with increasing pace in  
86 several affected areas, there is a need for immediate targeted action.

87

88         These high-risk procedures have implications for organization and medical practice  
89 of hospital care during this outbreak. Health policymakers everywhere plan for pandemics  
90 because their decisions can cause sharp shocks to societies and require a substantial and  
91 massive change in health system capacity [4]. These problems, caused by the COVID-19,  
92 emphasizes the importance of analyzing the epidemiological data worthwhile. The COVID-  
93 19 studies have typically been focused on the initial clinical characteristics and the  
94 epidemiological description [5]. A majority of infected patients had mild to severe lung  
95 abnormalities on their chest CT scans when they were discharged from the hospital. Experts  
96 believe such groups may need closer follow-ups [6].

97

98           According to our understanding, most of the studies related to this outbreak identify  
99 the epidemiology and clinical characteristics of infected patients [7], the genomic  
100 classification of the virus [8], and trials for global health governance [9]. COVID-19  
101 Cohorts in the literature are either retrospective or in a short duration (less than three  
102 months) [10–12]. However, to the best of our knowledge, there is no study examining the  
103 changing status of this virus and its psychological impact on the infected patients in the  
104 Middle East. Although the epidemic is still ongoing, initial lessons from its spread can help  
105 inform public health officials and medical practitioners to combat its progression.  
106 Accordingly, long-term prospective Cohorts are valuable studies in this pandemic.

107

108           Iran is one of the countries with a high prevalence of COVID-19. It has been  
109 revealed that half of the Iranians have limited health literacy, which is more common in  
110 exposed groups, such as unemployed people, homemakers, and older people [13]. Isfahan,  
111 the largest city in central Iran, with about 23000 positive corona cases, is among the three  
112 top Iranian cities with a high outbreak. For the improvement of future preparedness plans  
113 and provide a critical assessment of the resources and actionable items for stopping  
114 COVID-19 spread, utilizing lessons learned from the coronavirus outbreaks in hot zones  
115 could be helpful.

116

117           In this article, we present an effort to introduce an open-cohort from Isfahan,  
118 Khorshid COVID Cohort (KCC) study, to compile and analyze epidemiological outbreak  
119 information of COVID-19 infected patients. The objectives of our study are to provide a  
120 longitudinal overview of the patients' condition and identify different related risk factors.  
121 This longitudinal study aimed to analyze the following signs and symptoms findings in

122 patients with COVID-19 pneumonia for temporal changes and establish the incidence of  
123 psychological disorders and related prevalent symptoms after discharge from the hospital.

124

125 It is the first study where the temporal progression between infected patients in the  
126 Middle East is explored, to the best of our knowledge. Our research data are looked-for  
127 developing evidence-driven policies to reduce the adverse effects of the increased outbreak  
128 and psychological impacts. It may help government agencies and policy health makers  
129 protect the psychological well-being of society in the face of the COVID-19 outbreak in  
130 Iran and different parts of the world.

131

## 132 **Materials and methods**

### 133 **Study population**

134

135 In this prospective hospital-based surveillance study, patients admitted for COVID-19  
136 from February 2020 until September 2020 in the Khorshid Hospital in Isfahan were  
137 recruited (Fig 1). Khorshid is the referral hospital for COVID-19 adults in Isfahan. About  
138 fifty percent of the entire COVID-19 population from Isfahan refers to this hospital.

139

140 In this study, we diagnosed the COVID-19 patients based on the Chinese COVID-19  
141 diagnosis and treatment guidelines, and the WHO provisional advice [14]. Then, in case of  
142 a positive polymerase chain reaction (PCR) or compatible Chest computed High-resolution  
143 CT (HRCT) scan with COVID-19, the patients were recruited in this study. The ethics

144 committee of the Isfahan University of Medical Sciences (IUMS) and the other national  
145 authorities approved the study (IR.MUI.MED.REC.1399.029). The experimental protocol  
146 was also conformed to the Declaration of Helsinki. Also, the entire subjects gave written  
147 informed consent to the experimental procedure. The written informed consent was given  
148 by the first relative family of patients with severe conditions. No minors participated in our  
149 study. This Cohort has two phases. The first phase is on the admission information on  
150 hospitalized patients until discharge or death. In contrast, the second phase is related to  
151 patients discharged from the hospital for future symptoms or social factors. Six-hundred  
152 patients were enrolled in the first phase, while four-hundred ninety patients with complete  
153 information were analyzed in this paper.

154

155

156 **Fig 1. The scheme of the Khorshid COVID Cohort (KCC) study.**

157

## 158 **Baseline information collection**

159

160 We obtained the information related to demographic, socioeconomic status (SES),  
161 medical history, underlying chronic diseases, chest computed tomographic (CT) scans,  
162 signs, symptoms, laboratory findings, treatment (including oxygen support, antibiotics,  
163 antiviral therapy, corticosteroid therapy) during the hospital admission, and outcome data  
164 from patients medical records by Table 1 checklist. The body temperatures of the patients  
165 were taken at least four times a day. The detection of nucleic acid from the SARS-CoV-2 in  
166 upper respiratory specimens was qualitatively assessed using the PCR test. The PCR was

167 performed once for admission. Moreover, the Charlson Comorbidity Index (CCI) [15], an  
 168 indicator of comorbidity, was calculated for each COVID-19 patient.

169

170

171 **Table 1. Checklist of following patients admitted to the hospital.**

Name:		Family:		
<b>Sex:</b>	Male	Female		
Date of Birth:				
The number of family members:				
<b>Occupation:</b>	Employed	Unemployed		
Height:		Weight:		
<b>Education:</b>	Illiterate	College	Diploma	Graduated
<b>Smoking status:</b>	Yes	No		
<b>Tobacco usage:</b>	Yes	No		
Residence Address:		Postal Code:		
<b>Quarantine status before admission:</b>		Yes	No	
<b>First Symptoms</b>				
Sneeze	Runny Nose	Dry Cough	Phlegm Cough	Headache
Body Pain	Abdominal pain		Vomiting	Diarrhea
Chest Pain	Fatigue	Shortness of Breath		Fever
Duration Of having Symptoms (Days):				
<b>Same symptoms In Family:</b>			Yes	No
<b>Travel History:</b>		Where (country/City):		When (Date):
<b>Getting influenza vaccine since September:</b>		Yes	No	
Risk Factors				



<b>Patients with Immunodeficiency</b>					
Taking corticosteroids or other immunosuppressive drugs			Malignancies		
Organ transplant	HIV	Chemotherapy History			
<b>Patients with Underlying Disease</b>					
CVD	Hypertension	Respiratory Disease		Diabetes	
COPD	CKD	Dialysis history			
Vital Symptoms:	BP	T	PR	RR	O <sub>2</sub> Sat
<b>Laboratory Findings:</b>					
Drug Hx:	CRP:	Hb:	WBC:	LYM:	PMN:
PLT:	CXR:	CT scan Results:			
Treatment Strategy					
Outpatients Treatment:					
Inpatients Treatment:					
Suggested Treatment:					

172

173

## 174 **Laboratory findings**

175

176 Pharyngeal swab samples were collected for the COVID-19 test on arrangement.

177 Blood samples were collected from each participant, and routine blood test, including

178 Lymphocyte count (LYM), Platelet, Neutrophil (NEU), and White blood cell (WBC)

179 counts, Hemoglobin, Sodium (Na), Potassium (K), Blood urea nitrogen (BUN), Blood  
180 creatinine (Cr), Blood Calcium (Ca), Potassium (P), and Magnesium (Mg) were performed  
181 on the blood samples. Furthermore, blood biochemistry parameters such as C-reactive  
182 protein (CRP), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Alanine  
183 aminotransferase (ALT), Urea, as well as lactate dehydrogenase (LDH) and Albumin were  
184 assessed using HITACHI 7600-020 automated biochemistry analyzer. Other requested  
185 parameters on admission included troponin and EKG.

## 186 **Imaging protocol**

187 We acquired the entire chest CT images using a 64-slice Philips scanner, with low-  
188 dose protocol, between patients in the supine position, without the injection of contrast, and  
189 at full inspiration. The images were evaluated by two radiologists with experience in thorax  
190 imaging. A senior investigator with at least ten years of experience at interpreting chest CT  
191 images resolved any disagreement. The following characteristics were recorded for each  
192 CT scan: distribution (craniocaudal, and transverse), the pattern, and disease severity  
193 according to a semi-quantitative scoring system [16]. Each CT scan was sub-classified  
194 according to published RSNA guidelines to the following four groups: typical,  
195 indeterminate, atypical, and negative [17].

## 196 **Discharge criteria**

197 Patients presenting the following criteria were discharged: per evaluation of the  
198 treating physician, the clinical symptoms significantly improved (respiratory rate <20, pulse  
199 rate <100, oxygen saturation of 92% while the patient was breathing ambient air), AND the  
200 body temperature to be returned to normal for more than two days without any antipyretic  
201 medications, AND normal swallow for the solid oral medication (whole tablets and  
10

202 capsules), AND passing until 14 days after the onset of symptoms for patients without  
203 suitable caring system, AND good facilities for quarantine at home [18].

## 204 Follow-up

205

206 The total follow-up time lasts for one year in our study (The 1st, 4th, 12th weeks,  
207 and the first year). The following information of the discharged patients are being recorded:  
208 clinical signs and symptoms at home, possible COVID-19 recurrence, underlying diseases  
209 in their family, psychological symptoms, sleep quality, and related problems (Table 2).  
210 Discharged patients are being followed up by telephone in the first and fourth weeks to  
211 obtain whether they had any symptoms presented in Table 2. In the 12th week and the first  
212 year, each patient attends the hospital to complete the Patient Health Questionnaire-9  
213 (PHQ-9) and the Depression Anxiety Stress Scales (DASS-21) [19]. Moreover, clinical  
214 symptoms and the respiratory function (e.g., maximal inspiratory pressure (MIP), maximal  
215 expiratory pressure (MEP), and forced vital capacity (FVC), and forced expiratory  
216 volume  $\square$  one second (FEV1)) are being determined in the last two follow-ups.

217

218 **Table 2. Checklist of following patients discharged from the hospital.**

Name:	Family:			
Date of discharge				
Time of follow up	First	Second	Third	Fourth
Sex:	Male	Female		
First Symptoms				
	Runny Nose	Dry Cough	Phlegm Cough	Headache
Body Pain	Abdominal pain		Vomiting	Diarrhea

Chest Pain	Fatigue	Shortness of Breath		Fever
Sleep disorder	Yes	NO		
Decreased appetite	Yes	NO		
Reduced sense of smell (hyposmia)	Yes	<input checked="" type="checkbox"/>	NO	<input checked="" type="checkbox"/>
Weight Loss	Yes	NO		

219

220 We used the self-report PHQ-9 questionnaire to measure the depression severity,  
 221 with the total scores labeled as the following: severe depression (15–21), moderate  
 222 depression (10–14), mild depression (5–9), and no depression (0–4) [20]. Depression,  
 223 Anxiety, and Stress (DASS-21), a.k.a. Mental health status was measured based on  
 224 previous research [21]. The stress subscale was assessed using question numbers one, six,  
 225 eight, eleven, twelve, fourteen, and eighteen. The total stress subscale score was separated  
 226 into five groups: extremely severe stress (35–42), severe stress (27–34), moderate stress  
 227 (19–26), mild stress (11–18), and normal (0–10). The anxiety subscale was estimated using  
 228 question numbers two, four, seven, nine, fifteen, nineteen, and twenty. The anxiety subscale  
 229 score was also divided into five groups: extremely severe anxiety (20–42), severe anxiety  
 230 (15–19), moderate anxiety (10–14), mild anxiety (7–9), and normal (0–6). The depression  
 231 subscale was formed using questions three, five, ten, thirteen, sixteen, seventeen, and  
 232 twenty-one. The total depression subscale score was classified as extremely severe  
 233 depression (28–42), severe depression (21–27), moderate depression (13–20), mild  
 234 depression (10–12), and normal (0–9). It was shown that the DASS is a reliable and valid  
 235 method in measuring mental health between the Iranian population [22]. Note that the  
 236 DASS was previously used in the literature for the other coronavirus version like SARS  
 237 [23,24].

## 238 **Outcomes**

239

240           The initial results for the admitted patients were the following: Vital signs  
241 improvement, including SpO<sub>2</sub>, pulse and respiratory rate, blood pressure, temperature,  
242 intubation rate, death, and length of stay at the hospital. The secondary outcomes are  
243 impaired pulmonary function, later signs and symptoms, psychotic disorders, sleep  
244 disorders, and sustained end-organ failure. Moreover, The primary composite endpoint  
245 (PCEP), defined as death, the use of mechanical ventilation, or admission to an intensive  
246 care unit (ICU) [25], is reported in this paper.

247

248           The research team of professionals from Khorshid Hospital and clinical faculty  
249 members of Isfahan University of medical sciences cross-checked the data. A trained team  
250 of researchers independently entered the data into a computer-based database. In a case of  
251 missing in the raw data, the coordinators were requested for clarification to contact the  
252 corresponding clinicians. We obtained data from their pre-admission information based on  
253 medical histories and through contact with their close relatives considering medical records  
254 from previous hospital visits for patients who had consciousness problems on admission.  
255 Further details of the KCC based on the STROBE statement were provided (S1 File). Such  
256 big data is being analyzed by our data mining and biostatistical teams.

257

## 258 **Data analysis**

259

260           First, we entered the data into the Epi-Info 3.5.3 program  
261 (<https://www.cdc.gov/epiinfo/>). Then, the data were analyzed using STATA v12.0

262 (StataCorp, College Station, TX). The patient characteristics were reported as a percentage  
263 for categorical and mean (SD) for continuous data. The endpoint in this study was death or  
264 cure from the entire COVID-19-related causes. We confirmed the endpoint by reviewing  
265 hospital medical registration or by calling using the registered phone number. When the  
266 study period finishes, individuals alive after a follow-up time are censored. Accordingly,  
267 the subject outcome variable is death or censored after the follow-ups. In this manuscript,  
268 Hazard ratios and 95% confidence intervals for PECP associated with different baseline  
269 factors were estimated using Cox proportional-hazards regression models.

270

271 We use survival analysis to identify the connection between the patient's attributes  
272 with time from initial admission to death or the end of the follow-up after discharge are  
273 considered as covariates. The life table is used to estimate survival after the first admission,  
274 and a log-rank test is used for survival curves comparison according to different events.  
275 Time-dependent Cox regression is used to calculate the adjusted hazard rate to determine  
276 independent predictors of time to death [26]. Statistical tests were two-sided, and P-values  
277 less than 0.05 were considered to indicate statistical significance.

## 278 **Results and discussion**

279

280 Descriptive statistics were calculated for socioeconomic, demographic  
281 characteristics, clinical symptoms and health service utilization, contact history, and  
282 additional health information variables (Table 3). A total of 490 first COVID-19 cases with  
283 complete information were analyzed in this manuscript, with the average age of  
284  $56.58 \pm 15.09$  years (39%, female) admitted to the Khorshid hospital from February 2020.  
285 Eight percent of the admitted patients were transferred to the intensive care unit (ICU)

286 (48% male). Thirty-four patients (7%) died. The top three leading causes of admission  
 287 were: fever (77%), dry cough (73%), and fatigue (69%). Sneeze (10%), runny nose (14%),  
 288 and abdominal pain (17%) were the least frequent symptoms among COVID-19 patients.  
 289 The top three prevalent comorbidities with COVID-19 were hypertension (35%), diabetes  
 290 (28%), and ischemic heart disease (14%). The characteristics of 76 patients with pneumonia  
 291 with a negative PCR test and CT-scan were provided in Table 3 as the control group. The  
 292 clinical symptoms of the control and COVID-19 groups were similar, except for fatigue and  
 293 dry cough. The control group was hospitalized due to the similar characteristics to COVID-  
 294 19 patients during the pandemic. The information of this group was provided instead of that  
 295 of healthy subjects, as the discrimination between pneumonia and COVID-19 could be  
 296 valuable.

297

298 **Table 3. Demographic, SES, comorbidities, signs and symptoms, vital symptoms, and**  
 299 **laboratory findings of 490 patients admitted to a COVID-19 referral hospital in**  
 300 **Isfahan.**

Patients characteristics	COVID-19 (N = 490)	Composite events		P-value <sup>a</sup>	Control (N=76)	P-value <sup>b</sup>
		Yes (n=90)	No (n=400)			
<b>Age, years</b>	56.58±15.09	61.32±16.9	55.52±14.4	<0.00	58.41±19.1	0.428
		9	5	1	4	
<b>Sex (female)</b>	191 (39%)	24 (27%)	167 (42%)	0.010	38 (50%)	0.069
<b>Occupation (Employed)</b>	193 (45%)	30 (43%)	163 (46%)	0.811	29 (38%)	0.804
<b>Marital Status</b>				0.689		0.127
Single	15 (3%)	3 (3%)	12 (3%)		6 (8%)	
Married	470 (96%)	87 (97%)	383 (96%)		68 (90%)	

Divorced or widowed	5 (1%)	0 (0%)	5 (1%)		2 (2%)	
<b>subjects with infected family members</b>	34 (7%)	4 (4%)	30 (8%)	0.171	11 (14%)	0.157
<b>Symptom duration, day</b>	7.5±4.4	5.3±3.0	7.6±4.4	0.010	6.1±5.8	0.014
<b>Smoking status (yes)</b>	69 (14%)	16 (18%)	53 (13%)	0.456	10 (13%)	0.626
<b>Travel history to the high-risk regions (Yes)</b>	88 (18%)	11 (12%)	77 (19%)	0.458	4 (5%)	0.025
<b>Quarantine before admission (Yes)</b>	441 (90%)	78 (87%)	363 (91%)	0.014	59 (78%)	0.928
<b>Comorbidities (yes)</b>						
Hypertension	171 (35%)	36 (40%)	135 (34%)	0.347	32 (42%)	0.208
Ischemic heart disease	69 (14%)	16 (18%)	53 (13%)	0.210	17 (22%)	0.035
Diabetes	137 (28%)	33 (37%)	104 (26%)	0.026	21 (28%)	0.936
Immunological problems	1 (0.02%)	0 (0%)	1 (0.3%)	0.824	0 (0%)	0.692
Acute kidney disease	15 (3%)	7 (8%)	8 (2%)	0.008	4 (5%)	0.494
COPD	10 (2%)	5 (6%)	5 (1%)	0.151	7 (9%)	<0.001
Cancer	15 (3%)	6 (7%)	9 (2%)	0.060	2 (3%)	0.979
CCI	2.25±2.10	3.23±2.27	2.09±2.02	<0.001	-	-
<b>Signs and symptoms (yes)</b>						
Sneeze	49 (10%)	9 (10%)	40 (10%)	0.535	3 (4%)	0.176



Runny nose	69 (14%)	8 (9%)	61 (15%)	0.111	8 (11%)	0.697
Fever	377 (77%)	70 (78%)	307 (77%)	0.488	49 (64%)	0.069
Fatigue	338 (69%)	72 (80%)	266 (67%)	0.020	34 (45%)	0.005
Dry cough	358 (73%)	61 (68%)	297 (74%)	0.185	45 (59%)	0.002
Headache	230 (47%)	42 (47%)	188 (47%)	0.936	22 (29%)	0.169
Shortness of Breath (dyspnea)	328 (67%)	63 (70%)	265 (66%)	0.371	50 (66%)	0.624
Diarrhea	147 (30%)	22 (24%)	125 (31%)	0.499	11 (14%)	0.070
Sore throat	127 (26%)	27 (30%)	100 (25%)	0.001	15 (20%)	0.693
Vomiting	122 (25%)	22 (25%)	100 (25%)	0.556	17 (22%)	0.949
Abdominal pain	83 (17%)	15 (17%)	68 (17%)	0.567	6 (8%)	0.107
<b>Vital Symptoms</b>						
Pulse Rate, /min	95.29±17.52	96.86±19.4 6	95.18±17.0 5	0.379	96.69±20.4 3	0.471
Respiratory Rate, /min	22.87±10.05	24.44±9.80	22.54±10.0 1	0.079	23.45±5.74	0.570
SpO2, %	89.25±7.70	82.57±13.1 6	90.87±4.58	<0.00 1	87.61±7.06	0.053
Systolic blood pressure, mm Hg	133.27±19.71	134.08±22. 27	132.08±18. 90	0.328	135.96±24. 19	0.208
Diastolic blood pressure, mmHg	82.12±29.41	79.13±17.5 7	82.75±13.4 3	0.245	80.16±15.9 3	0.632
<b>Laboratory Findings</b>						
PCR results (Positive)	335 (77%)	71 (87%)	264 (75%)	0.012	0 (0%)	<0.001

White blood cell count, $\times 10^9$ /L	6.05 $\pm$ 3.08	7.48 $\pm$ 4.40	5.73 $\pm$ 2.59	<0.001	8.55 $\pm$ 4.66	<0.001
Neutrophil count, $\times 10^9$ /L	7.32 $\pm$ 1.12	8.01 $\pm$ 1.04	7.16 $\pm$ 1.01	<0.001	7.58 $\pm$ 1.35	0.065
Lymphocyte count, $\times 10^9$ /L	2.09 $\pm$ 0.98	1.49 $\pm$ 0.91	2.23 $\pm$ 0.94	<0.001	1.69 $\pm$ 1.13	0.001
Platelet count, $\times 10^9$ /L	190.35 $\pm$ 72.51	178.13 $\pm$ 65.07	193.18 $\pm$ 73.90	0.051	188.59 $\pm$ 74.74	0.829
Hemoglobin, g/dL	13.28 $\pm$ 1.78	12.79 $\pm$ 2.08	13.40 $\pm$ 1.68	0.001	12.50 $\pm$ 2.15	0.002
CRP, mg/L	29.74 $\pm$ 20.35	34.16 $\pm$ 24.57	28.74 $\pm$ 19.24	0.160	28.57 $\pm$ 20.72	0.655
LDH, U/L	616.77 $\pm$ 314.22	828.94 $\pm$ 426.67	544.67 $\pm$ 226.25	<0.001	735.50 $\pm$ 185.74	0.109
AST, U/L	46.68 $\pm$ 49.05	62.60 $\pm$ 61.11	49.95 $\pm$ 45.04	<0.001	40.31 $\pm$ 16.28	0.033
ALT, U/L	32.50 $\pm$ 32.33	44.07 $\pm$ 54.49	29.76 $\pm$ 23.59	0.002	27.85 $\pm$ 13.84	0.397
ALP, U/L	168.18 $\pm$ 96.84	195.83 $\pm$ 181.24	162.46 $\pm$ 60.31	0.001	186.42 $\pm$ 63.64	0.009
Na, meq/L	134.75 $\pm$ 3.48	134.13 $\pm$ 4.27	134.89 $\pm$ 3.26	0.040	135.06 $\pm$ 2.96	0.244
K, mmol/L	3.76 $\pm$ 0.32	3.90 $\pm$ 0.45	3.73 $\pm$ 0.30	0.014	3.82 $\pm$ 0.44	0.419
Ca, mg/dL	8.55 $\pm$ 0.73	8.33 $\pm$ 0.95	8.60 $\pm$ 0.67	0.001	8.67 $\pm$ 0.72	0.121
P, mg/dL	2.94 $\pm$ 0.76	3.22 $\pm$ 1.10	2.88 $\pm$ 0.65	<0.001	3.17 $\pm$ 0.84	0.054

Mg, mg/dL	1.93±0.25	1.95±0.24	1.93±0.25	0.500	1.98±0.29	0.404
BUN, mg/dL	19.49±12.96	29.91±21.0 9	17.07±8.57	0.001	21.59±8.29	0.122
Cr, mg/dL	1.19±0.96	1.83±1.73	1.04±0.58	<0.00 1	1.23±0.27	0.449

301 CCI: Charlson Comorbidity Index.

302 <sup>a</sup>Comparison between composite event groups.

303 <sup>b</sup>Comparison between COVID-19 and control groups.

304

305 The Cox Proportional-Hazards Model was used for PCEP (Table 4). Age was  
 306 categorized based on the Petrilli et al. study [27], and the reference category was set to 0-44  
 307 years old. The normal range of oxygen saturation (95%-100%) was set as the reference  
 308 category in SpO<sub>2</sub>. The developed survival model showed very good diagnostic accuracy  
 309 (AUC= 0.85) for discriminating COVID-19 patients with/without PCEP.

310

311 **Table 4. The Cox Proportional-Hazards Model for PCEP.**

Factor	HR	CI 95%	p-value
Sex (male)	1.505	[0.944,2.401]	0.086
Age cat0	ref		
Age cat1	1.278	[0.529,3.087]	0.586
Age cat2	1.295	[0.576,2.909]	0.532
Age cat3	2.077	[0.925,4.666]	0.077

Age cat4	1.512	[0.662,3.453]	0.327
SpO2 cat0	ref		
SpO2 cat1	0.674	[0.270,1.681]	0.397
SpO2 cat2	2.495	[1.075,5.793]	<b>0.033</b>
SpO2 cat3	6.275	[2.537,15.524]	<b>&lt;0.001</b>
lymphopenia	3.457	[2.189,5.457]	<b>&lt;0.001</b>
thrombocytopenia	1.598	[1.042,2.449]	<b>0.0315</b>
AUC	0.85	[0.78,0.91]	

312 Age categories were 0-44, 45-54, 55-64, 65-74, >= 75 years (cat0-cat4); SpO2 categories  
 313 were <80%, 80%-89%, 90%-94%, 95%-100% (cat3-cat0); Lymphopenia: lymphocyte  
 314 count < 109 /L; Thrombocytopenia: Platelet count < 150×109 /L; AUC: area under the  
 315 ROC.

316

317 Among 456 COVID-19 patients discharged from the hospital, three patients died  
 318 during the first follow up (i.e., the first week) while one more patient died at the second  
 319 follow up (the fourth week). Those patients who died were from the PCEP group. The  
 320 clinical symptoms of the patients during four weeks of follow up are shown in Table 5.

321

322

323

324

325

326 **Table 5. The clinical symptoms of the COVID-19 patients during four weeks of follow-**  
 327 **up.**

symptoms (yes)	The first week (n=453)			The fourth week (n=452)		
	Non-Severe <sup>a</sup> (n=400)	Severe (n=53)	P-value	Non-severe (n=400)	Severe (n=52)	P-value
Runny nose	3 (0.75%)	1 (1.89%)	0.406	6 (1.50%)	1 (1.92%)	0.578
Fever	7 (1.75%)	1 (1.89%)	1.000	4 (1.00%)	1 (1.92%)	0.459
Fatigue	43 (10.75%)	7 (13.21%)	0.592	43 (10.75%)	7 (13.46%)	0.320
Dry cough	115 (28.75%)	9 (16.98%)	0.071	73 (18.25%)	8 (15.38%)	0.612
Headache	5 (1.25%)	1 (1.89%)	0.528	10 (2.50%)	2 (3.85%)	0.637
Shortness of Breath (dyspnea)	86 (21.50%)	10 (18.87%)	0.660	59 (14.75%)	10 (19.23%)	0.398
Diarrhea	7 (1.75%)	1 (1.89%)	1.000	1 (0.25%)	0 (0.00%)	1.000
Sore throat	0 (0.00%)	0 (0.00%)	-	3 (0.75%)	1 (1.92%)	0.388
Vomiting	14 (3.50%)	3 (5.66%)	0.435	11 (2.75%)	1 (1.92%)	1.000
Abdominal pain	12 (3.00%)	1 (1.89%)	1.000	5 (1.25%)	1 (1.92%)	0.522
Sleep disorder	18 (4.50%)	4 (7.55%)	0.309	21 (5.25%)	4 (7.69%)	0.513
Decreased	10 (2.50%)	4 (7.55%)	0.069	13 (3.25%)	2 (3.85%)	0.687

appetite						
Hyposmia	12 (3.00%)	1 (1.89%)	1.000	18 (4.50%)	3 (5.77%)	0.723
Weight loss	18 (4.50%)	3 (5.66%)	0.725	31 (7.75%)	6 (11.54%)	0.349

328 <sup>a</sup>Sever group had composite events while non-severe groups did not have composite

329 events.

330

331 Among 490 COVID-19 patients, 90 patients had positive PCEP. The following  
332 characteristics were not significantly different in PCEP positive and negative groups: BMI,  
333 occupation, marital status, number of infected family members, smoking status, and travel  
334 history to the high-risk regions. However, the distribution of age ( $p<0.001$ ), sex ( $p=0.010$ ),  
335 symptom duration ( $p=0.010$ ), and quarantine before admission ( $p=0.0140$ ) were  
336 significantly different in PCEP positive and negative groups. Having analyzed the  
337 comorbidities in PCEP positive and negative groups, although hypertension, Ischemic heart  
338 disease, Immunological problems, COPD, and cancer were not significant, diabetes  
339 ( $p=0.026$ ), and acute kidney disease ( $p=0.008$ ) were significant.

340

341 Among signs and vital symptoms, only SpO<sub>2</sub> ( $p<0.001$ ), fatigue ( $p=0.020$ ), and  
342 Sore throat ( $p=0.001$ ) were significantly different in both groups. However, except for Mg  
343 ( $p=0.500$ ), platelet count ( $p=0.051$ ), and CRP ( $p=0.160$ ), other laboratory findings were  
344 significant in the analyzed groups. Notably, elevated white blood cells ( $p<0.001$ ), and  
345 neutrophil counts ( $p<0.001$ ), BUN ( $p=0.001$ ), LDH ( $p<0.001$ ), AST ( $p<0.001$ ), ALT  
346 ( $p=0.002$ ), ALP ( $p=0.001$ ), Cr ( $p<0.001$ ), and K ( $p=0.014$ ) were seen in PCEP positive  
347 groups compared with the negative groups. However, the platelet counts decreased in the

348 PCEP group, but it was not significant ( $p=0.051$ ). Moreover, the lymphocyte counts  
349 significantly decreased in the PCEP positive class ( $p<0.001$ ).

350

351 The median time from admission to discharge was 5.0 days (interquartile range 3.0-  
352 8.0). The transmission route was by a history of exposure to the epidemic area (16%) or  
353 close contact with family members (25%), among which 10% of patients had both  
354 exposures. The average symptom duration was 7.5 days. A significant reduction of this  
355 time was observed in PCEP positive group respect to the negative group ( $p=0.010$ ).  
356 Representative samples of the COVID-19 patients were provided at  
357 <https://figshare.com/s/ef91187fb69a051b8396> (50 subjects with negative PCEP and ten  
358 subjects with positive PCEP).

359

360 The significant factors for PCEP survival analysis were Oxygen saturation  $< 80\%$   
361 ( $HR=6.275$ ), lymphopenia ( $HR=3.457$ ), Oxygen saturation (80%-90%) ( $HR=2.495$ ), and  
362 thrombocytopenia ( $HR=1.598$ ). It was found that hypoxemia is associated with in-hospital  
363 mortality and the oxygen saturation levels below 90% have high risks [28], which is in  
364 agreement with our results (Table 4). Lymphopenia is also associated with the disease  
365 severity of COVID-19 [29,30]. Moreover, thrombocytopenia was shown to be associated  
366 with the severity and mortality of COVID-19 [31,32]. Although not significant, older age is  
367 associated with mortality [33], similar to our findings. In our study, the PCEP risk was  
368 higher in men than women ( $HR=1.505$ ; Tables 3 and 4), which is similar to Pérez-López et  
369 al. [34].

370

371 The clinical symptoms of the COVID-19 subjects discharged from the hospital were  
372 shown in Table 5 for the first- and fourth-week follow-ups. Such symptoms were similar in

373 severe and non-severe cases, and the top three symptoms in the entire follow-ups and severe  
374 or non-severe groups were dry cough, dyspnea, and fatigue, among which fatigue and cough  
375 were also observed in the three-month follow-ups of the study performed by Zhao et al.  
376 [35]. Moreover, the prevalence of sleep disorder, hyposmia, and weight loss increased from  
377 the first- to the fourth-week follow-ups (Table 5), emphasizing the long-term effect of  
378 COVID-19.

379

380 This Cohort aims to identify the problems presented in COVID-19 patients from  
381 first-time admission until death or one year after discharge. It is the first study in which  
382 COVID-19 patients are followed up to identify trends in signs and symptoms in an outbreak  
383 hot zone in the Middle East, to the best of our knowledge. It is required to perform  
384 thorough research on the novel, appearing in human infectious coronaviruses. It is then  
385 possible to explain their pathogenic mechanisms route and to recognize potential medicine.  
386 When considering the social effects of the outbreak, it might be possible to develop useful  
387 preventive and therapeutic medicaments. Moreover, the long-term analysis of psychological  
388 distress and mental illness symptoms of such patients after hospital discharge was taken  
389 into account in our Cohort. Such issues are fundamental, in general, in this pandemic [36].

390

391 According to our laboratory-confirmed cases, the common clinical manifestations  
392 were fever (77%), dry cough (73%), fatigue (69%), and shortness of breath (67%). The  
393 three most common clinical manifestations were consistent with the studies in China  
394 [7,25,37,38]. In laboratory examination results, less than 20% of the patients had decreased  
395 white blood cell counts. Also, the percentage of lymphocytopenia was 4%. It was in  
396 contrast with other studies that reported that most of their patients had this problem [25,39].

397



398 Previous studies demonstrated that the elderly and those with underlying disorders  
399 (i.e., cardiovascular diseases, diabetes, hypertension, and chronic obstructive pulmonary  
400 disease) developed rapidly into ARDS, even leading to ICU admission or death [7].  
401 Although our findings presented that the death and ICU admission rate was 7% and 14%, a  
402 similar condition was observed. Cardiac complications, including heart failure, arrhythmia,  
403 or myocardial infarction, are common in patients with pneumonia.

404

405 It might be possible to reduce the probability of COVID-19 incidence and distress,  
406 reporting high-risk pathogens and social effects of this disease, which can help health  
407 policymakers lead reasonable policies when using our cohort results. Most people show  
408 mild symptoms. However, it may progress to ARDS, pneumonia, and multi-organ  
409 dysfunction in older people and those with comorbidities [40]. Many patients who survive  
410 acute viral pneumonia have impaired functions and health status in the first few months of  
411 recovery. However, long-term sequelae are still mostly unknown [41]. Patients who  
412 survived an episode of ARDS may have marked dyspnea and severe respiratory  
413 physiological abnormalities. Although a one-year post-ICU follow-up study showed that  
414 survivors of A(H1N1)-associated ARDS had minor lung disabilities [42], both obstructive  
415 and restrictive deficits have been reported in patients with ARDS. The ARDS survivors  
416 often suffer prolonged myopathy limiting daily living activities, post-traumatic stress  
417 disorder (PTSD), and an increased number of deaths after apparent recovery. Such  
418 problems usually exist for more than three months. Moreover, many patients show  
419 continuous neurocognitive dysfunction for one to two years. When managing these  
420 problems supportively, the knowledge of the PTSD persistency in such patients is required  
421 [43].

422

423

424           The medical and public health infrastructure and the economy were affected by this  
425 new virus outbreak worldwide [44]. Several studies have reported adverse psychological  
426 complications, including confusion, symptoms of traumatic stress, and anger in cases who  
427 encountered stressful situations. The long quarantine period, fear of disease, boredom,  
428 despair, inadequate food shortages, insufficient information, stigma, and financial loss are  
429 known as stressors in the COVID-19 epidemic [45,46]. Along with this, the primary  
430 purpose of this study is to identify psychological problems among discharged patients for  
431 one year.

432

433           It takes time to see how the virus affects our lives here in Iran and other parts of the  
434 world. It is also possible to have similar future outbreaks. Besides limiting this outbreak,  
435 preventive programs must be planned for such problems. It is of great importance when  
436 considering the warning by the WHO chief as "the virus will be with us for a long time."

437

438           It must be mentioned that self-reporting used for the first two follow-ups has some  
439 limitations compared to face-to-face interviews for the second and third follow-ups. Also,  
440 psychological studies do not necessarily probe psychological services efficacy. Thus,  
441 dynamic observations and more follow-ups are necessary. The larger sample size is also  
442 required for result verification, which is available during the Cohort. Apart from such  
443 limitations, it is possible to perform a risk assessment and to use medical data mining for  
444 diagnosis and prognosis to identify complex interactions. Multistate models are the focus of  
445 our future work to provide the stacked probability plots and to predict the length of the  
446 hospital (or ICU) stay of COVID-19 patients.

447

## 448 **Conclusions**

449           The COVID-19 outbreak has become a clinical danger to the general population and  
450 healthcare workers worldwide. However, knowledge about the trend of this novel virus,  
451 which leads to different symptoms and outcomes, remains limited. The practical option of  
452 different treatment, underlying disease, clinical findings, and different symptoms or signs  
453 on the disease prognosis is under evaluation and development. What we can do now is to  
454 design a cohort to follow patients to identify the underlying trend based on different  
455 outcomes and their risk assessment. It may assist healthcare policymakers and government  
456 agencies, and in the managing of health and resources following this pandemic.

457

## 458 **Acknowledgments**

459

460           We would like to acknowledge the Khorshid hospital nurses and interns for this  
461 study, who recruited patients and collected follow-up data. Most importantly, we would  
462 like to acknowledge all the patients who consented to participate in this study. The authors  
463 are thankful to Prof. Martin Wolkewitz from the University of Freiburg for valuable  
464 comments.

## 465 **References**

466

- 467 1. Liu S, Yang L, Zhang C, Xiang Y-T, Liu Z, Hu S, et al. Online mental health services in China  
468 during the COVID-19 outbreak. *Lancet Psychiatry*. 2020;7: e17–e18. doi:10.1016/S2215-

- 469 0366(20)30077-8
- 470 2. Jiang S, Shi Z-L. The First Disease X is Caused by a Highly Transmissible Acute Respiratory  
471 Syndrome Coronavirus. *Virol Sin.* 2020. doi:10.1007/s12250-020-00206-5
- 472 3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real  
473 time. *Lancet Infect Dis.* 2020. doi:10.1016/S1473-3099(20)30120-1
- 474 4. MacIntyre R. The risk of selective investment in downstream pandemic planning. *Global  
475 Biosecurity.* 2019. p. 85. doi:10.31646/gbio.36
- 476 5. Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, et al.  
477 Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and  
478 critical appraisal. *BMJ.* 2020;369: m1328. doi:10.1136/bmj.m1328
- 479 6. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal Changes of CT Findings in 90  
480 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology.* 2020; 200843.  
481 doi:10.1148/radiol.2020200843
- 482 7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with  
483 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395: 497–506. doi:10.1016/S0140-  
484 6736(20)30183-5
- 485 8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology  
486 of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.*  
487 2020;395: 565–574. doi:10.1016/S0140-6736(20)30251-8
- 488 9. Rubin GJ, Wessely S. The psychological effects of quarantining a city. *BMJ.* 2020;368: m313.  
489 doi:10.1136/bmj.m313
- 490 10. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for  
491 patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur  
492 Respir J.* 2020;55. doi:10.1183/13993003.00524-2020
- 493 11. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-  
494 19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort  
495 study. *Lancet Infect Dis.* 2020. doi:10.1016/S1473-3099(20)30287-5
- 496 12. Khairat S, Meng C, Xu Y, Edson B, Gianforcaro R. Interpreting COVID-19 and Virtual Care  
497 Trends: Cohort Study. *JMIR Public Health Surveill.* 2020;6: e18811. doi:10.2196/18811
- 498 13. Montazeri A, Tavousi M, Rakhshani F, Azin SA, Jahangiri K, Ebadi M, et al. Health Literacy  
499 for Iranian Adults (HELIA): development and psychometric properties. *Payesh (Health  
500 Monitor).* 2014;13: 589–599. Available:  
501 [http://payeshjournal.ir/browse.php?a\\_id=279&sid=1&slc\\_lang=en](http://payeshjournal.ir/browse.php?a_id=279&sid=1&slc_lang=en)
- 502 14. Jernigan DB, CDC COVID-19 Response Team. Update: Public Health Response to the  
503 Coronavirus Disease 2019 Outbreak - United States, February 24, 2020. *MMWR Morb Mortal  
504 Wkly Rep.* 2020;69: 216–219. doi:10.15585/mmwr.mm6908e1
- 505 15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic  
506 comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40: 373–  
507 383. doi:10.1016/0021-9681(87)90171-8
- 508 16. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes On Chest CT  
509 During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology.* 2020;  
510 200370. doi:10.1148/radiol.2020200370

- 511 17. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological Society of  
512 North America Expert Consensus Statement on Reporting Chest CT Findings Related to  
513 COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of  
514 Radiology, and RSNA. *Radiology: Cardiothoracic Imaging*. 2020;2: e200152.  
515 doi:10.1148/ryct.2020200152
- 516 18. Guidance for discharge and ending isolation in the context of widespread community  
517 transmission of COVID-19 – first update. In: European Centre for Disease Prevention and  
518 Control [Internet]. 8 Apr 2020 [cited 7 May 2020]. Available:  
519 [https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-](https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolation)  
520 [isolation](https://www.ecdc.europa.eu/en/publications-data/covid-19-guidance-discharge-and-ending-isolation)
- 521 19. Ell K, Unützer J, Aranda M, Sanchez K, Lee P-J. Routine PHQ-9 depression screening in  
522 home health care: depression, prevalence, clinical and treatment characteristics and screening  
523 implementation. *Home Health Care Serv Q*. 2005;24: 1–19. doi:10.1300/J027v24n04\_01
- 524 20. Kocalevent R-D, Hinz A, Brähler E. Standardization of the depression screener patient health  
525 questionnaire (PHQ-9) in the general population. *Gen Hosp Psychiatry*. 2013;35: 551–555.  
526 doi:10.1016/j.genhosppsy.2013.04.006
- 527 21. Le TA, Le MQT, Dang AD, Dang AK, Nguyen CT, Pham HQ, et al. Multi-level predictors of  
528 psychological problems among methadone maintenance treatment patients in difference types  
529 of settings in Vietnam. *Subst Abuse Treat Prev Policy*. 2019;14: 39. doi:10.1186/s13011-019-  
530 0223-4
- 531 22. Sahebi A, Asghari MJ, Salari RS. Validation of Depression Anxiety and Stress Scale (DASS-  
532 21) for an Iranian Population. *Scientific Journal Management System*. 2005;1: 36–54.  
533 Available: [http://jip.azad.ac.ir/article\\_512443.html](http://jip.azad.ac.ir/article_512443.html)
- 534 23. Sim K, Huak Chan Y, Chong PN, Chua HC, Wen Soon S. Psychosocial and coping responses  
535 within the community health care setting towards a national outbreak of an infectious disease. *J*  
536 *Psychosom Res*. 2010;68: 195–202. doi:10.1016/j.jpsychores.2009.04.004
- 537 24. Leung GM, Lam T-H, Ho L-M, Ho S-Y, Chan BHY, Wong IOL, et al. The impact of  
538 community psychological responses on outbreak control for severe acute respiratory syndrome  
539 in Hong Kong. *J Epidemiol Community Health*. 2003;57: 857–863.  
540 doi:10.1136/jech.57.11.857
- 541 25. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of  
542 Coronavirus Disease 2019 in China. *N Engl J Med*. 2020. doi:10.1056/NEJMoa2002032
- 543 26. Moore DF. *Applied Survival Analysis Using R*. Springer International Publishing; 2016.  
544 Available: <https://play.google.com/store/books/details?id=7bRjjwEACAAJ>
- 545 27. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors  
546 associated with hospital admission and critical illness among 5279 people with coronavirus  
547 disease 2019 in New York City: prospective cohort study. *BMJ*. 2020;369: m1966.  
548 doi:10.1136/bmj.m1966
- 549 28. Xie J, Covassin N, Fan Z, Singh P, Gao W, Li G, et al. Association Between Hypoxemia and  
550 Mortality in Patients With COVID-19. *Mayo Clin Proc*. 2020;95: 1138–1147.  
551 doi:10.1016/j.mayocp.2020.04.006
- 552 29. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with  
553 severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis.  
554 *Int J Infect Dis*. 2020;96: 131–135. doi:10.1016/j.ijid.2020.04.086

- 555 30. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts disease  
556 severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther.*  
557 2020;5: 33. doi:10.1038/s41392-020-0148-4
- 558 31. Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association between platelet  
559 parameters and mortality in coronavirus disease 2019: Retrospective cohort study. *Platelets.*  
560 2020;31: 490–496. doi:10.1080/09537104.2020.1754383
- 561 32. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus  
562 disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta.* 2020;506: 145–148.  
563 doi:10.1016/j.cca.2020.03.022
- 564 33. Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V, Fácila  
565 L, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With  
566 611,583 Subjects. *J Am Med Dir Assoc.* 2020;21: 915–918. doi:10.1016/j.jamda.2020.05.045
- 567 34. Pérez-López FR, Tajada M, Savirón-Cornudella R, Sánchez-Prieto M, Chedraui P, Terán E.  
568 Coronavirus disease 2019 and gender-related mortality in European countries: A meta-  
569 analysis. *Maturitas.* 2020;141: 59–62. doi:10.1016/j.maturitas.2020.06.017
- 570 35. Zhao Y-M, Shang Y-M, Song W-B, Li Q-Q, Xie H, Xu Q-F, et al. Follow-up study of the  
571 pulmonary function and related physiological characteristics of COVID-19 survivors three  
572 months after recovery. *EClinicalMedicine.* 2020;25: 100463.  
573 doi:10.1016/j.eclinm.2020.100463
- 574 36. Rajkumar RP. COVID-19 and mental health: A review of the existing literature. *Asian J*  
575 *Psychiatr.* 2020;52: 102066. doi:10.1016/j.ajp.2020.102066
- 576 37. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138  
577 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.  
578 *JAMA.* 2020. doi:10.1001/jama.2020.1585
- 579 38. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical  
580 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a  
581 descriptive study. *Lancet.* 2020;395: 507–513. doi:10.1016/S0140-6736(20)30211-7
- 582 39. Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel  
583 coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J .* 2020.  
584 doi:10.1097/CM9.0000000000000744
- 585 40. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). *Indian J Pediatr.* 2020;87:  
586 281–286. doi:10.1007/s12098-020-03263-6
- 587 41. Chan KS, Zheng JP, Mok YW, Li YM, Liu YN, Chu CM, et al. SARS: prognosis, outcome  
588 and sequelae. *Respirology.* 2003;8 Suppl: S36–40. doi:10.1046/j.1440-1843.2003.00522.x
- 589 42. Luyt C-E, Combes A, Becquemin M-H, Beigelman-Aubry C, Hatem S, Brun A-L, et al. Long-  
590 term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. *Chest.*  
591 2012;142: 583–592. doi:10.1378/chest.11-2196
- 592 43. Spencer-Segal JL, Hyzy RC, Iwashyna TJ, Standiford TJ. Psychiatric Symptoms in Survivors  
593 of Acute Respiratory Distress Syndrome. Effects of Age, Sex, and Immune Modulation. *Ann*  
594 *Am Thorac Soc.* 2017;14: 960–967. doi:10.1513/AnnalsATS.201606-468OC
- 595 44. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbutto V, Veronese N, et al. Coronavirus  
596 Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. *Int J*  
597 *Environ Res Public Health.* 2020;17. doi:10.3390/ijerph17082690

- 598 45. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003  
599 SARS pandemic and the 2020 novel coronavirus epidemic in China. *J Autoimmun.* 2020;  
600 102434. doi:10.1016/j.jaut.2020.102434
- 601 46. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The  
602 psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet.*  
603 2020;395: 912–920. doi:10.1016/S0140-6736(20)30460-8
- 604

## 605 **Supporting information**

606 **S1 File. The specification of the KCC based on STROBE Statement.**

607

